Blood test may predict liver cancer treatment success

NCT ID NCT07303712

Recruiting now Knowledge-focused Sponsor: Palo Alto Veterans Institute for Research Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether a blood test (liquid biopsy) can predict how well liver cancer responds to a type of internal radiation called Y90 radioembolization. Researchers will take blood samples from 12 adults with liver cancer before and after treatment to look for tumor cells and DNA. The goal is to see if early changes in these markers can forecast treatment success, potentially guiding future care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma Neoplastic Cells, Circulating

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA (HCC)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

VA Palo Alto Health Care System
RECRUITING

Palo Alto, California, 94304, United States

Contact Phone: •••-•••-••••